Are Weight-Loss Drugs Covered by Insurance Plans? - GoodRx
Are Weight-Loss Drugs Covered by Insurance Plans? GoodRx
Zepbound News
Zepbound Sales Climb 49% to $5.35 Billion as Lilly Sells More Weight-Loss Medicine at Lower Prices - Medical Daily
Zepbound Sales Climb 49% to $5.35 Billion as Lilly Sells More Weight-Loss Medicine at Lower Prices Medical Daily
Can Storage Mistakes Ruin a GLP-1 Drug? - Medscape
Can Storage Mistakes Ruin a GLP-1 Drug? Medscape
Eli Lilly Revenue Climbs on Demand for Obesity Drugs - WSJ
Eli Lilly Revenue Climbs on Demand for Obesity Drugs WSJ
GLP-1 compounder issues recall for copycat Zepbound - BioPharma Dive
GLP-1 compounder issues recall for copycat Zepbound BioPharma Dive
Eli Lilly Earnings: Medicare Zepbound Demand Outpaced Our Expectations, but Shares Overvalued - Morningstar
Eli Lilly Earnings: Medicare Zepbound Demand Outpaced Our Expectations, but Shares Overvalued Morningstar
Zepbound and Gastroparesis: How Common It Is and How to Avoid It - Ro
Zepbound and Gastroparesis: How Common It Is and How to Avoid It Ro
Understanding Zepbound for Diabetes: What Patients Should Know - ΕΜΥ
Understanding Zepbound for Diabetes: What Patients Should Know ΕΜΥ
Eli Lilly lifts revenue outlook as weight-loss shot demand soars, shares jump - Reuters
Eli Lilly lifts revenue outlook as weight-loss shot demand soars, shares jump Reuters
Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock closed at a record high. - MarketWatch
Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock closed at a record high. MarketWatch
Eli Lilly Soars 5% as Mounjaro and Zepbound Demand Drives $5.5 Billion Guidance Raise - Yahoo Finance
Eli Lilly Soars 5% as Mounjaro and Zepbound Demand Drives $5.5 Billion Guidance Raise Yahoo Finance
The Oral GLP-1 Tracker: Foundayo, Wegovy pill rally toward previous records - Fierce Pharma
The Oral GLP-1 Tracker: Foundayo, Wegovy pill rally toward previous records Fierce Pharma
Eli Lilly raised its outlook for a third time this year thanks to soaring Zepbound sales - Quartz
Eli Lilly raised its outlook for a third time this year thanks to soaring Zepbound sales Quartz
Eli Lilly: Mounjaro And Zepbound Keep The Growth Story Alive (NYSE:LLY) - Seeking Alpha
Eli Lilly: Mounjaro And Zepbound Keep The Growth Story Alive (NYSE:LLY) Seeking Alpha
Lilly's obesity drug strength fuels record rally, Wall Street optimism - Reuters
Lilly's obesity drug strength fuels record rally, Wall Street optimism Reuters
Live Updates: Insurance Coverage for GIP and GLP-1 Agonists Like Zepbound & Wegovy in 2026 - GoodRx
Live Updates: Insurance Coverage for GIP and GLP-1 Agonists Like Zepbound & Wegovy in 2026 GoodRx
Whats in Zepbound: Understanding the Composition of This Medicine - ΕΜΥ
Whats in Zepbound: Understanding the Composition of This Medicine ΕΜΥ
GLP-1 coverage is shrinking: What Wegovy and Zepbound users need to check during open enrollment - Medical Daily
GLP-1 coverage is shrinking: What Wegovy and Zepbound users need to check during open enrollment Medical Daily
Does TRICARE Cover Zepbound? Coverage, Rules, and Costs - Ro
Does TRICARE Cover Zepbound? Coverage, Rules, and Costs Ro
Understanding Zepbound Weight Loss Injections: What Is Known and What Needs Verification - emy
Understanding Zepbound Weight Loss Injections: What Is Known and What Needs Verification emy
Ozempic vs Wegovy vs ZepBound: Understanding the Differences Between These Medications - EMY
Ozempic vs Wegovy vs ZepBound: Understanding the Differences Between These Medications EMY
Zepbound and Breast Cancer: What Is Known and What Needs Clarification - ΕΜΥ
Zepbound and Breast Cancer: What Is Known and What Needs Clarification ΕΜΥ
Eli Lilly Raises 2026 Sales Outlook on Mounjaro, Zepbound Strength - Yahoo Finance
Eli Lilly Raises 2026 Sales Outlook on Mounjaro, Zepbound Strength Yahoo Finance
ZepBound FDA Approval: Understanding the Regulatory Status and What It Means - ΕΜΥ
ZepBound FDA Approval: Understanding the Regulatory Status and What It Means ΕΜΥ
Zepbound Side Effects Long Term: What Is Known About Extended Use - ΕΜΥ
Zepbound Side Effects Long Term: What Is Known About Extended Use ΕΜΥ
GLP-1 recall: Mounjaro, Zepbound ingredient risk raised to second-highest level - MassLive.com
GLP-1 recall: Mounjaro, Zepbound ingredient risk raised to second-highest level MassLive.com
US judge declines to block Lilly’s Zepbound ads in Novo false advertising case - The Pharma Letter
US judge declines to block Lilly’s Zepbound ads in Novo false advertising case The Pharma Letter
Lilly reports Phase IIIb data on Taltz and Zepbound combination - Clinical Trials Arena
Lilly reports Phase IIIb data on Taltz and Zepbound combination Clinical Trials Arena
Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial - STAT
Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial STAT
Experimental Lilly combination drug tops Zepbound in weight-loss trial - Reuters
Experimental Lilly combination drug tops Zepbound in weight-loss trial Reuters
Zepbound and Mounjaro may turn on the body’s calorie-burning brown fat - Science Daily
Zepbound and Mounjaro may turn on the body’s calorie-burning brown fat Science Daily
GLP-1 boom sparks a costly question: Who pays? - NewsNation
GLP-1 boom sparks a costly question: Who pays? NewsNation
Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion - CNBC
Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion CNBC
Eli Lilly study aims to bolster case for long-term Zepbound benefits - Fierce Healthcare
Eli Lilly study aims to bolster case for long-term Zepbound benefits Fierce Healthcare
Eli Lilly Stock Jumps on Monster Earnings as Finance Chief Eyes Next Growth Engine - Barron's
Eli Lilly Stock Jumps on Monster Earnings as Finance Chief Eyes Next Growth Engine Barron's
More children under 12 in US are being prescribed weight-loss drugs, study finds - Reuters
More children under 12 in US are being prescribed weight-loss drugs, study finds Reuters
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo - Fierce Biotech
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo Fierce Biotech
Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher - Yahoo Finance
Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher Yahoo Finance
Menopause: How GLP-1s and Hormone Therapy Can Affect Weight Loss - Healthline
Menopause: How GLP-1s and Hormone Therapy Can Affect Weight Loss Healthline
Doctors: Stop GLP-1 use 1 to 2 months before trying to become pregnant - NewsNation
Doctors: Stop GLP-1 use 1 to 2 months before trying to become pregnant NewsNation